GLP-1 medicines and surgery / anaesthesia — what the guidance says

What the interaction is

GLP-1 receptor agonists, including semaglutide and tirzepatide, delay gastric emptying as part of their intended pharmacological action — it is one of the mechanisms contributing to reduced appetite and slower post-meal glucose rise. The same effect means that food or liquid consumed before a procedure may remain in the stomach for longer than standard fasting guidelines assume, because those guidelines were developed largely without accounting for medicines that deliberately slow gastric transit.

The perioperative risk in plain English

Standard preoperative fasting instructions (commonly a period without solid food and a shorter period without clear fluids) are designed to reduce the volume of stomach contents present at the time of anaesthetic induction, because retained gastric contents increase the risk of regurgitation and pulmonary aspiration once airway reflexes are suppressed by general anaesthesia or deep sedation. If gastric emptying is pharmacologically delayed, a patient who has followed standard fasting instructions could, in principle, still have more gastric content than expected. This is the underlying mechanism behind the guidance discussed below — it is a risk-probability question, not a claim that every patient on a GLP-1 medicine will have a full stomach at the time of surgery.

How anaesthesia societies frame the risk

The American Society of Anesthesiologists issued a consensus-based guidance statement in June 2023 — the first major society-level position addressing this question directly — which discussed preoperative symptom screening and circumstances in which a case might warrant full-stomach precautions or a deferred procedure. In the UK, perioperative guidance addressing GLP-1 receptor agonists has been developed through bodies including the Centre for Perioperative Care, working alongside the Royal College of Anaesthetists and affiliated anaesthesia societies, with briefings issued from 2023 onward. Both the US and UK positions describe themselves as consensus-based and subject to revision as further clinical experience and evidence accumulate, and subsequent joint statements from multiple bodies have refined the initial guidance. This page reports that societies have taken the issue seriously enough to issue formal guidance; it does not reproduce specific hold-timing recommendations from any single statement, both because those recommendations vary between issuing bodies and because they are described by their own authors as provisional.

What clinicians and patients should communicate before elective surgery

Published guidance generally emphasises early disclosure: telling the surgical team and anaesthetist about current GLP-1 or dual-agonist use — including the specific medicine, dose and recent dosing history — as early as possible in the booking process, rather than at the pre-assessment appointment or on the day of surgery. Guidance also generally highlights the value of reporting gastrointestinal symptoms such as ongoing nausea, vomiting, reflux, bloating or a sense of delayed fullness, since these may factor into the anaesthetist's individualised assessment of aspiration risk. Point-of-care gastric ultrasound has been discussed as a developing tool some centres use to assess gastric content status directly, as an alternative or supplement to a fixed hold period, though availability and standardisation vary. None of this constitutes a substitute for the specific instructions given by the treating surgical and anaesthetic team.

What the evidence does not establish

Current guidance in this area is consensus-based rather than derived from large randomised trials measuring aspiration event rates directly tied to GLP-1 dosing intervals. The absolute magnitude of increased aspiration risk associated with GLP-1 therapy — as opposed to the theoretical mechanism — is not precisely quantified in the published literature, and society statements have generally been explicit about this limitation rather than presenting a settled evidence base. Guidance continues to be revised as more clinical experience and, ideally, more direct outcome data become available. This page reflects that state of evolving guidance and should be read alongside — not instead of — the current published position from the relevant anaesthesia or perioperative care body and, most importantly, direct advice from the clinicians managing your specific procedure.

Frequently asked questions

Why do anaesthetists ask about GLP-1 medicines before surgery?

GLP-1 receptor agonists delay gastric emptying as an on-target pharmacological effect, which raises the theoretical possibility that a patient presenting for surgery under standard fasting instructions could still have solid or liquid stomach contents present at the time of anaesthetic induction. Retained gastric contents are a recognised risk factor for pulmonary aspiration during general anaesthesia and deep sedation, which is why anaesthetists now routinely ask about GLP-1 use during preoperative assessment.

Does this mean GLP-1 medicines are unsafe for people having surgery?

No. The concern is a perioperative risk-management question about gastric content status at the time of anaesthesia, not a statement that GLP-1 therapy is generally unsafe or that surgery should be avoided. Anaesthesia societies have issued guidance precisely so that this risk can be assessed and managed proactively, rather than leaving it unaddressed.

Will I be told to stop my GLP-1 medicine before surgery?

Possibly, but the decision — including whether to hold the medicine, for how long, and what dietary or assessment measures to use instead — is an individualised clinical judgement made by the anaesthetist and surgical team, taking account of the specific medicine, dose, indication, procedure urgency and the patient's gastrointestinal symptoms. This page does not set out hold-before-surgery timings, and readers should not use any generic timing rule as a substitute for their own care team's instructions.

What did the 2023 ASA consensus statement actually say?

The American Society of Anesthesiologists published a consensus-based guidance statement in June 2023 that was the first major anaesthesia-society position on perioperative GLP-1 management. It set out considerations for preoperative assessment — including symptom screening for nausea, vomiting, reflux and abdominal distension — and discussed circumstances in which a case might be treated as a full-stomach precaution or postponed for further assessment. The statement has been influential but is explicitly described by the ASA itself as consensus-based rather than derived from robust outcome trial data, and it has been revisited as further evidence and clinical experience accumulate.

Is UK guidance the same as the US ASA guidance?

The general direction — recognising delayed gastric emptying as a perioperative consideration and building it into preoperative assessment — is shared across UK and US guidance, but specific wording and recommendations differ, and both have been described by their issuing bodies as evolving. UK perioperative guidance has been developed through bodies including the Centre for Perioperative Care working with the Royal College of Anaesthetists and affiliated societies. The current published guidance from the relevant body is the authoritative reference, not a cross-jurisdictional summary.

What symptoms should I tell my anaesthetist about before surgery?

Guidance generally emphasises disclosing current GLP-1 or dual-agonist use, the specific medicine and dose, timing of the most recent dose relative to the procedure, and any gastrointestinal symptoms such as ongoing nausea, vomiting, reflux, bloating or a sense of delayed fullness after meals. This symptom picture feeds into the anaesthetist's individualised risk assessment. This page does not replace the specific preoperative questionnaire or assessment used by your surgical centre.

Does this apply to sedation for procedures like endoscopy, not just general anaesthesia?

Yes, the same gastric-emptying consideration has been discussed in relation to procedural sedation, including for upper gastrointestinal endoscopy, because aspiration risk relates to airway protection and gastric content status generally, not solely to general anaesthesia. Guidance for endoscopy and other sedation contexts has evolved alongside general surgical anaesthesia guidance, and the team performing the procedure is best placed to advise on their specific protocol.

Can a full stomach be checked before anaesthesia instead of stopping the medicine?

Point-of-care gastric ultrasound has been discussed in the anaesthesia literature as one possible tool for assessing gastric content status immediately before a procedure, as an alternative or supplement to a fixed hold period. This is a developing area of clinical practice and equipment/expertise availability varies between centres; it is not universally available or standardised, and whether it is used in a specific case is a decision for the treating anaesthetic team.

Has this guidance changed since it was first published?

Yes. Anaesthesia societies including the ASA have explicitly described their initial 2023 statements as consensus-based positions intended to be revisited as more evidence accumulates, and subsequent joint statements and clarifications have followed from multiple bodies. This is an area of active guidance development rather than a single fixed protocol, which is part of why this page does not attempt to reproduce a specific timing table.

What should I do if I have elective surgery booked and I'm on a GLP-1 medicine?

Tell your surgical team and anaesthetist that you are taking a GLP-1 or dual-agonist medicine as early as possible in the booking process, ideally well before the day of surgery, so that any assessment or planning can happen in advance rather than at short notice. Follow the specific instructions given by your own care team rather than a generic online timing rule, since guidance is genuinely still evolving and individual circumstances (medicine, dose, indication, symptoms, procedure type) all affect the assessment.